The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin’s lymphoma, according to Seattle Genetics. The supplemental Biologics License ... Read more